Sotlar K, Diemer D, Stubner A, Menton S, Menton M, Dietz K, Wallwiener D, Bültmann B
Institut für Pathologie, Universität Tübingen.
Verh Dtsch Ges Pathol. 2005;89:195-200.
The oncogenic potential of the high-risk human papillomavirus (HR-HPV) genotypes depends on the expression of the viral oncogenes E6 and E7. Thus, the detection of these transcripts could serve as a factor in the evaluation of a woman's risk of development of cervical intraepithelial neoplasia (CIN).
A nested RT-PCR assay for the detection of E6/E7 oncogene transcripts of all known HR-HPV genotypes was established. Cervical scrapes of 779 HR-HPV-DNA-positive women exhibiting all grades of CIN were examined.
Spliced E6/E7 oncogene transcripts of all the HR-HPVs were detected in numerous samples. In 459 cases with agreement between the cytologic and histologic findings, the prevalence increased with lesion severity: CIN 0, 18%; CIN I, 58%; CIN II, 77%; CIN III, 84%. While sensitivity and negative predictive value of HR-HPV DNA-positivity for the detection of a CIN lesion were significantly (p < 0.0001) higher than those of E6/E7 mRNA positivity (90.3% vs. 65.5% and 93% vs. 83.1%), the opposite was true for the specificity and positive predictive value (72.8 % vs. 95.2%) and 65.1% vs. 88.5%, p < 0.0001). Preliminary follow-up data in 120 initially HPV-16 DNA-positive women revealed the development, persistence or progression of a CIN lesion in 33% (8/24) of HR-HPV DNA-positive and E6/E7 mRNA-negative women, compared to 93% (66/71, p < 0.0001) in women in whom transcriptional activity of the E6/E7 oncogenes was detectable.
Besides the identification of HPV DNA, the detection of HR-HPV E6/E7 oncogene transcripts may serve as a valuable tool in increasing the specificity of HPV testing.
高危型人乳头瘤病毒(HR-HPV)基因型的致癌潜力取决于病毒癌基因E6和E7的表达。因此,检测这些转录本可作为评估女性发生宫颈上皮内瘤变(CIN)风险的一个因素。
建立了一种巢式逆转录聚合酶链反应(RT-PCR)检测方法,用于检测所有已知HR-HPV基因型的E6/E7癌基因转录本。对779例呈现各级CIN的HR-HPV-DNA阳性女性的宫颈刮片进行了检查。
在众多样本中检测到了所有HR-HPV的剪接E6/E7癌基因转录本。在459例细胞学和组织学检查结果一致的病例中,患病率随病变严重程度增加:CIN 0为18%;CIN I为58%;CIN II为77%;CIN III为84%。虽然HR-HPV DNA阳性检测CIN病变的敏感性和阴性预测值显著高于E6/E7 mRNA阳性(分别为90.3%对65.5%和93%对83.1%,p<0.0001),但特异性和阳性预测值情况相反(分别为72.8%对95.2%以及65.1%对88.5%,p<0.0001)。对120例最初HPV-16 DNA阳性女性的初步随访数据显示,HR-HPV DNA阳性且E6/E7 mRNA阴性的女性中有33%(8/24)发生、持续存在或进展为CIN病变,而在可检测到E6/E7癌基因转录活性的女性中这一比例为93%(66/71,p<0.0001)。
除了鉴定HPV DNA外,检测HR-HPV E6/E7癌基因转录本可能是提高HPV检测特异性的一项有价值的工具。